Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
October 2024—Thermo Fisher Scientific announced it received FDA 510(k) clearance to market its Optilite Freelite assays for the evaluation of monoclonal gammopathy of undetermined significance. The assays measure kappa and lambda free light chains in serum, enabling the identification of even small concentrations of monoclonal FLC proteins undetectable by serum protein electrophoresis.
October 2024—Smart In Media announced an AI enhancement to its PathoZoom LiveView microscope camera and software. This system incorporates “AI on the fly,” which allows users to run AI routines from their own microscope. Users select a region of interest in the field of view and AI results are returned in a few seconds. PDL-1, Ki67, ER, and PR are available now on Smart In Media’s AI menu.
October 2024—Pillar Biosciences has entered into a strategic partnership with AstraZeneca to expand laboratory access to molecular testing using rapid next-generation sequencing–based liquid biopsy tumor profiling panels for detecting genetic cancer variants. The partnership aims to make liquid biopsy tumor profiling more accessible to local laboratories, clinicians, and patients through rapid and affordable kitted NGS testing solutions.
October 2024—Qiagen has released a new version of its clinical decision support software Qiagen Clinical Insight Interpret. The latest release builds on the advanced artificial intelligence capabilities of QCI Interpret, including AI-derived literature searches and AI-trained phenotype-driven ranking.
October 2024—Bio-Rad Laboratories has launched annexin V conjugated to eight StarBright dyes—SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, and SBY800. The Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options, and enable full use of all common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright dyes, reduces spillover and spreading to provide high-resolution data.
October 2024—Maine Molecular Quality Controls now offers Spotfire RSP Controls for the Biofire Spotfire Respiratory/Sore Throat Panel Mini assay. The controls are intended for use as an external assayed quality control to monitor performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of pathogens on all Biofire Spotfire respiratory assays performed on the Spotfire system. The kit contains six positive and six negative controls in 300-µL tubes. Maine Molecular Quality Controls 207-885-1072
October 2024—Johnson & Johnson announced Food and Drug Administration approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
October 2024—Adaptimmune Therapeutics announced FDA accelerated approval for Tecelra (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive, and whose tumor expresses the MAGE-A4 antigen as determined by FDA-approved or -cleared companion diagnostic devices. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent on verification and description of clinical benefit in a confirmatory trial.
October 2024—Roche announced the launch of the Cobas Respiratory flex test, the first to use Roche’s novel and proprietary TAGS (temperature-activated generation of signal) technology. Developed by Roche scientists, TAGS technology uses multiplex PCR testing combined with color, temperature, and data processing to identify as many as 15 pathogens in a single PCR test. The Respiratory flex test can detect up to 12 of the most common respiratory viruses, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2. The test runs on the high-throughput Cobas 5800, 6800, and 8800 analyzers.
October 2024—Bio-Rad Laboratories has announced a partnership with Sysmex America in which Bio-Rad’s Unity Next Peer QC software is now available with Sysmex CA-Series and CS-Series hemostasis systems for the United States.
